Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Masahiro Kashiwaba
Validation of the 21-Gene Test as a Predictor of Clinical Response to Neoadjuvant Hormonal Therapy for ER+, HER2-negative Breast Cancer: The TransNEOS Study
Breast Cancer Research and Treatment
Cancer Research
Oncology
Related publications
Evaluating the 21-Gene Assay Recurrence Score® as a Predictor of Clinical Response to 24 Weeks of Neoadjuvant Exemestane in Estrogen Receptor-Positive Breast Cancer
International Journal of Clinical Oncology
Medicine
Surgery
Oncology
Hematology
Neoadjuvant Chemotherapy and Bevacizumab for HER2-Negative Breast Cancer
New England Journal of Medicine
Medicine
Hormone Receptor-Negative as a Predictive Factor for Pathologic Complete Response to Neoadjuvant Therapy in Breast Cancer
Einstein (São Paulo, Brazil)
Medicine
Neoadjuvant Palbociclib on ER+ Breast Cancer (N007): Clinical Response and EndoPredict Value
Endocrine-Related Cancer
Cancer Research
Endocrinology
Oncology
Metabolism
Diabetes
18f-Fluorodeoxyglucose (FDG) PET/CT After Two Cycles of Neoadjuvant Therapy May Predict Response in HER2-negative, but Not in HER2-positive Breast Cancer
Oncotarget
Oncology
Clinical Significance of Quantitative HER2 Gene Amplification as Related to Its Predictive Value in Breast Cancer Patients in Neoadjuvant Setting
OncoTargets and Therapy
Oncology
Pharmacology
Breast Cancer Stem Cells in HER2-negative Breast Cancer Cells Contribute to HER2-mediated Radioresistance and Molecular Subtype Conversion: Clinical Implications for Serum HER2 in Recurrent HER2-negative Breast Cancer
Oncotarget
Oncology
De-Escalated Therapy for HR+/HER2+ Breast Cancer Patients With Ki67 Response After 2 Weeks Letrozole: Results of the PerELISA Neoadjuvant Study
Annals of Oncology
Medicine
Oncology
Hematology
Cost-Effectiveness Analysis of Neoadjuvant Chemotherapy With Zoledronic Acid for HER2-Negative Breast Cancer in Japan: The JONIE1 Study
Health
